Three Stocks Estimated To Be Undervalued In November 2024

In This Article:

As global markets navigate the uncertainties of the incoming Trump administration and fluctuating interest rate expectations, investors are keenly observing sector-specific impacts such as deregulation in financials and energy, alongside challenges faced by healthcare and electric vehicle sectors. In this environment, identifying undervalued stocks becomes crucial; these are companies whose current market prices may not fully reflect their intrinsic value or future potential amidst shifting economic policies and market dynamics.

Top 10 Undervalued Stocks Based On Cash Flows

Name

Current Price

Fair Value (Est)

Discount (Est)

Alltop Technology (TPEX:3526)

NT$279.00

NT$554.65

49.7%

Lindab International (OM:LIAB)

SEK226.60

SEK450.18

49.7%

SeSa (BIT:SES)

€76.00

€150.71

49.6%

S-Pool (TSE:2471)

¥344.00

¥681.84

49.5%

Solum (KOSE:A248070)

₩17280.00

₩34265.45

49.6%

Guangdong Fenghua Advanced Technology (Holding) (SZSE:000636)

CN¥16.20

CN¥32.31

49.9%

XD (SEHK:2400)

HK$22.40

HK$44.60

49.8%

AirBoss of America (TSX:BOS)

CA$4.25

CA$8.45

49.7%

Intellian Technologies (KOSDAQ:A189300)

₩44600.00

₩88907.79

49.8%

iFLYTEKLTD (SZSE:002230)

CN¥53.07

CN¥105.85

49.9%

Click here to see the full list of 935 stocks from our Undervalued Stocks Based On Cash Flows screener.

Let's explore several standout options from the results in the screener.

BioArctic

Overview: BioArctic AB (publ) is a Swedish company focused on developing biological drugs for central nervous system disorders, with a market cap of SEK15.80 billion.

Operations: Revenue Segments (in millions of SEK):

Estimated Discount To Fair Value: 29.2%

BioArctic AB is trading at a significant discount, approximately 29.2% below its estimated fair value of SEK252.65, based on discounted cash flow analysis. Despite recent financial setbacks with a net loss of SEK 145.62 million over nine months, BioArctic's revenue is projected to grow rapidly at 49.2% annually, outpacing the Swedish market and indicating potential for future profitability within three years. Recent positive developments include the EMA's recommendation for lecanemab's approval in Europe.

OM:BIOA B Discounted Cash Flow as at Nov 2024
OM:BIOA B Discounted Cash Flow as at Nov 2024

Range Intelligent Computing Technology Group

Overview: Range Intelligent Computing Technology Group Company Limited develops data centers and other technology campuses, with a market cap of CN¥60.22 billion.

Operations: The company's revenue primarily comes from IDC Services, amounting to CN¥8.08 billion.